New hope for tough blood cancers: experimental drug enters human testing
NCT ID NCT05828589
First seen Jun 27, 2026 · Last updated Jul 15, 2026 · Updated 2 times
Summary
This early-stage study is testing an experimental drug called BGB-21447 in about 112 people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after prior treatments. The main goal is to find a safe dose and check for side effects, while also seeing if the drug can shrink tumors. Participants will take the drug alone, and the study will help decide if larger trials should move forward.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
51 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria 1. Confirmed diagnosis (per World Health Organization \[WHO\] guidelines, unless otherwise noted) of one of the following: Cohort A1 and Cohort A2: 1. R/R DLBCL (for Cohort A1 and Cohort A2.1) * High-grade B-cell lymphomas with translocations of MYC and Bcl-2 and/or Bcl-6 are not allowed in Cohort A1 but may be allowed in Cohort A2.1 2. R/R FL (for Cohort A1 and Cohort A2.2) 3. R/R MZL (for Cohort A1 and Cohort A2.2) 4. Transformed B-cell NHL (for Cohort A1 only) 5. Richter's transformation to DLBCL (for Cohort A1 only) 2. Measurable disease by computed tomography/magnetic resonance imaging. Exclusion Criteria: 1. Prior malignancy (other than the disease under study) within the past 2 years, except for curatively treated basal or squamous skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score ≤ 6 prostate cancer or lentigo maligna melanoma that has been curatively resected 2. Known central nervous system involvement by lymphoma/leukemia 3. Prior autologous stem cell transplant \< 3 months before the first dose of study drug. Or prior chimeric antigen receptor T-cell (CAR-T) therapy \< 3 months before the first dose of study drug 4. Prior allogeneic stem cell transplant. 5. Major surgery \< 4 weeks before the first dose of study treatment NOTE: Other protocol-defined Inclusion/Exclusion criteria may apply.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Refractory chronic lymphocytic leukemia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
Auckland City Hospital
Auckland, 1023, New Zealand
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105-2108, United States
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, 300020, China
-
Jiangsu Province Hospital
Nanjing, Jiangsu, 210029, China
-
Laura and Isaac Perlmutter Cancer Center At Nyu Langone Health
New York, New York, 10016-2708, United States
-
Linear Clinical Research
Nedlands, Western Australia, WA 6009, Australia
-
Linyi Peoples Hospital
Linyi, Shandong, 276000, China
-
Mater Cancer Care Centre
South Brisbane, Queensland, QLD 4101, Australia
-
Mission Cancer and Blood
Waukee, Iowa, 50263, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
Nyu Langone Health Perlmutter Cancer Center At Nyu Langone Hospital Long Island
Mineola, New York, 11501, United States
-
Peking University Third Hospital
Beijing, Beijing Municipality, 100000, China
-
Pindara Private Hospital
Benowa, Queensland, QLD 4217, Australia
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Shengjing Hospital of China Medical University
Shenyang, Liaoning, 110004, China
-
Sibley Memorial Hospital Johns Hopkins Medicine
Washington D.C., District of Columbia, 20016, United States
-
Sidney Kimmel Comprehensive Cancer At Johns Hopkins
Baltimore, Maryland, 21287, United States
-
The First Affiliated Hospital of Nanchang University Branch Donghu
Nanchang, Jiangxi, 330006, China
-
The First Affiliated Hospital of Nanchang University Branch Xianghu
Nanchang, Jiangxi, 332000, China
-
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215006, China
-
The First Peoples Hospital of Changzhou
Changzhou, Jiangsu, 213000, China
-
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242-1009, United States
-
Yichang Central Peoples Hospitaljiangnan Branch
Yichang, Hubei, 443001, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive antibody vs stem cell transplant: which keeps lymphoma at bay?
- Can three targeted drugs tame an aggressive blood cancer?
- Can a Multi-Drug combo outsmart resistant lymphoma?
- Can a new drug combo outsmart resistant lymphomas?
- Could adjusting chemo doses boost CAR T-Cell success against tough lymphoma?
- Engineered immune cells take on tough lymphomas